Paget ⚕️disease of breast ❤️1000+ questions & answers

By /
Paget disease of breast
Paget disease of breast

🎗️ Paget Disease of the Breast: A Comprehensive Clinical and Patient Guide

Paget disease of the breast (PDB), also known as mammary Paget disease, is a rare form of breast cancer that first becomes visible on the skin of the nipple and areola before a underlying tumor may be felt or detected. It is characterized by the intraepidermal presence of malignant glandular cells—known as Paget cells—within the nipple-areola complex (NAC), and it is almost always associated with an underlying in situ or invasive breast carcinoma in the same breast. The disease was first described by Sir James Paget in 1874, who recognized the eczematous nipple changes as a harbinger of underlying breast cancer. Despite its deceptively benign appearance, Paget disease represents a clinically significant malignancy that requires a high index of suspicion, prompt biopsy, and multidisciplinary management.

Paget disease of breast
Paget disease of breast

📋 ICD-10 Classification and Coding

In the International Classification of Diseases, Tenth Revision (ICD-10), Paget disease of the breast is coded under the parent category C50 — Malignant neoplasm of breast. The specific code depends on laterality:

  • C50.0 — Malignant neoplasm of nipple and areola of breast (Paget disease of the nipple)

  • C50.011 — Paget disease, right nipple

  • C50.012 — Paget disease, left nipple

  • C50.019 — Paget disease, unspecified nipple

In the AJCC TNM staging system, pure Paget disease of the nipple without an associated invasive carcinoma or DCIS in the underlying breast parenchyma is classified as Tis (Paget)—carcinoma in situ. When Paget disease is accompanied by a parenchymal carcinoma (DCIS or invasive ductal carcinoma), the tumor is staged according to the size and characteristics of the underlying parenchymal disease, although the presence of Paget disease should still be noted.

Paget disease of breast
Paget disease of breast

🔬 Types and Classification

Paget disease of the breast is not a single uniform entity. It is classified in several overlapping ways, each with distinct clinical and prognostic implications.

🩺 Clinical vs. Subclinical Forms

A 2023 study distinguished clinical Paget disease—in which areolar abnormalities are visible on examination—from subclinical/pathological Paget disease, in which the disease is identified microscopically without gross clinical changes. Most patients (approximately 83.5%) have HER2-positive or luminal HER2 molecular subtypes.

🧬 Classification by Underlying Disease

The most clinically useful classification system divides Paget disease into three categories based on the presence and type of underlying breast carcinoma:

  • PD-DCIS: Paget disease with underlying ductal carcinoma in situ—the most common presentation and the most favorable prognosis, with a 5-year survival rate of approximately 97.5%.

  • PD-IDC: Paget disease with underlying invasive ductal carcinoma—associated with a worse prognosis, with a 5-year survival rate of approximately 84.1%.

  • Pure PD: Paget disease alone, without identifiable DCIS or IDC in the underlying breast.

🔬 Paget Type vs. Pagetoid Type

Japanese classification systems distinguish Paget type (localized to the nipple epidermis and adjacent lactiferous ducts without an invasive mass) from Pagetoid type (associated with an invasive mass), which carries different prognostic and therapeutic implications.

🎨 Molecular Subtypes

Paget disease is predominantly HER2-positive—approximately 80% of cases show HER2 overexpression—and is frequently hormone receptor-negative (ER-positive in only 10–14% of cases; AR-positive in 71–88%). This molecular profile has significant implications for targeted therapy.

Paget disease of breast
Paget disease of breast

🧬 What Causes Paget Disease of the Breast?

The exact cause remains incompletely understood, but two principal theories exist:

The Epidermotropic Theory proposes that Paget cells are malignant ductal epithelial cells that migrate from an underlying in situ or invasive carcinoma through the lactiferous ducts to the epidermis of the nipple. This theory is supported by the frequent coexistence of underlying DCIS and the shared molecular profiles between Paget cells and the underlying carcinoma.

The In Situ Transformation Theory suggests that Paget cells arise from pluripotent keratinocyte stem cells within the nipple epidermis that undergo malignant transformation independently of an underlying breast carcinoma.

Regardless of the mechanism, all breast cancers—including Paget disease—begin with DNA changes that instruct cells to grow and multiply uncontrollably.

⚠️ Risk Factors

The risk factors for Paget disease mirror those for breast cancer generally:

  • Age: Most commonly diagnosed in postmenopausal women, with a peak incidence between 50 and 60 years of age; median age at diagnosis is approximately 61 years.

  • Family history of breast cancer.

  • Genetic mutations (BRCA1, BRCA2) may increase susceptibility.

  • Hormonal factors: Early menarche, late menopause, nulliparity, and prolonged hormone replacement therapy.

  • Lifestyle factors: Obesity, alcohol consumption, and lack of physical activity.

Male Paget disease is extremely rare, accounting for approximately 1.45% of all male breast cancers (compared with 0.68% of female breast cancers).

Paget disease of breast
Paget disease of breast

🛡️ How to Avoid and Prevent Paget Disease

There is no proven method to completely prevent Paget disease, and because it is a rare manifestation of breast cancer, prevention strategies are identical to those for breast cancer overall. These include:

  • Maintaining a healthy body weight and avoiding obesity.

  • Limiting alcohol consumption.

  • Engaging in regular physical activity (150–300 minutes of moderate exercise weekly).

  • Avoiding prolonged combined hormone replacement therapy.

  • Breastfeeding, which is associated with modestly reduced breast cancer risk.

  • For high-risk women with BRCA mutations, risk-reducing mastectomy and enhanced surveillance may be considered.

Because Paget disease often presents as a visible nipple change, awareness and prompt medical evaluation of any persistent nipple eczema, scaling, or discharge that does not respond to standard dermatologic treatment within two weeks is the most critical preventive strategy for avoiding diagnostic delay.

🩺 Early Signs and Common Symptoms

Paget disease typically presents with unilateral nipple-areola changes that may be mistaken for benign dermatitis or eczema. The classic clinical presentation is an eczematous, ulcerated, granular, or scaly nipple surface, often with nipple discharge. Symptoms usually begin in the nipple and may spread to the areola and surrounding breast skin.

📋 Common Symptoms

The most frequently reported symptoms include:

  • Flaky or scaly skin on the nipple.

  • Crusty, oozing, or hardened skin that resembles eczema on the nipple and/or areola.

  • Itching (pruritus), reported in approximately 14% of cases.

  • Burning sensation or pain, occurring in 15–25% of cases.

  • Straw-colored or bloody nipple discharge, reported in up to 39% of cases.

  • A turned-in (retracted) nipple.

  • A palpable lump in the breast (present in a minority of patients but associated with a worse prognosis).

  • Thickening of the breast skin.

A key clinical clue is that the “eczema” of Paget disease typically has a sharp border and does not respond to topical corticosteroids. The presence of a palpable breast mass alongside nipple changes significantly worsens prognosis—5-year survival drops from 92–94% without a mass to approximately 38–40% with a mass.

Paget disease of breast
Paget disease of breast

🖥️ Diagnosis: Imaging, Biopsy, and Biomarkers

The diagnosis of Paget disease requires a high index of suspicion and a multimodal approach combining clinical examination, imaging, and histopathology.

🩻 Imaging

Mammography is the initial imaging investigation, but it can be normal in up to 50% of cases of Paget disease. When abnormal, mammography may reveal nipple-areola changes, a mass, or microcalcifications.

Breast ultrasound is used to evaluate the breast parenchyma and regional lymph node basins.

Breast MRI plays a crucial role when mammography and ultrasound are negative. MRI provides superior sensitivity for detecting underlying DCIS or invasive disease that is occult on conventional imaging. MD Anderson’s algorithm recommends MRI with and without contrast when the nipple biopsy is positive but imaging is negative, with biopsy of any MRI-detected lesion. AGO guidelines similarly recommend MRI of the breast if other imaging is negative.

🔬 Biopsy

Full-thickness skin biopsy of the nipple-areola complex is the gold standard for diagnosis. This may be performed via punch biopsy or wedge excision, and must include all skin strata to ensure adequate sampling. If the initial biopsy is negative but clinical suspicion remains high, re-biopsy at 3 months is recommended if the lesion does not heal.

🧪 Immunohistochemistry and Biomarkers

Immunohistochemical staining is essential for confirming the diagnosis and guiding therapy. The standard panel includes ER, PR, HER2, and CK7:

  • CK7 positivity confirms glandular differentiation.

  • HER2 overexpression is present in approximately 80% of Paget disease cases.

  • ER positivity is uncommon (10–14%).

  • Androgen receptor (AR) positivity is frequent (71–88%).

Paget disease of breast
Paget disease of breast

💊 Treatment Options

Treatment of Paget disease is guided by the underlying breast cancer—its type, stage, and molecular profile—rather than by the nipple changes alone. A multidisciplinary approach involving surgical, medical, and radiation oncology is essential.

🔪 Surgery

Surgery is the cornerstone of treatment and may consist of mastectomy or breast-conserving surgery (BCS) with removal of the nipple-areola complex.

Mastectomy (total mastectomy) was historically the standard approach and remains common, particularly when there is extensive underlying disease or multicentricity. Breast-conserving surgery (central lumpectomy including the NAC) followed by whole-breast radiation therapy has emerged as a viable alternative for localized disease, with studies showing comparable survival outcomes. A SEER analysis found 5-year breast cancer-specific survival of 95.8% after BCS versus 94.1% after mastectomy (10-year: 93.4% vs. 92.2%), with no statistically significant difference.

Sentinel lymph node biopsy (SLNB) should be considered for patients with invasive disease or when mastectomy is performed, as axillary staging guides adjuvant therapy.

☢️ Radiation Therapy

Postoperative radiation therapy is recommended after breast-conserving surgery to reduce local recurrence risk. The NCCN guidelines note that radiation may be given after removal of the nipple-areola complex.

💊 Systemic Therapy

Chemotherapy, hormone therapy, and HER2-targeted therapy are used when there is underlying invasive carcinoma, based on the tumor’s stage and biology. For HER2-positive disease—which constitutes the majority of Paget cases—trastuzumab and pertuzumab are standard components of systemic therapy. Endocrine therapy (tamoxifen or aromatase inhibitors) is indicated for hormone receptor-positive disease.

For pure Paget disease (Tis) without invasive carcinoma, systemic chemotherapy is generally not indicated, but endocrine therapy may be considered for risk reduction if the underlying DCIS is ER-positive.

📊 Stages and TNM Classification

The staging of Paget disease depends on the presence and extent of underlying breast carcinoma:

  • Tis (Paget): Paget disease of the nipple without associated invasive carcinoma or DCIS in the underlying breast parenchyma—Stage 0.

  • When Paget disease is associated with DCIS or invasive carcinoma in the breast parenchyma, the tumor is staged according to the size and characteristics of the parenchymal disease (T1–T4), with nodal (N) and metastatic (M) status determining the overall stage.

Stage-specific 5-year relative survival for Paget disease with underlying invasive carcinoma follows the general breast cancer pattern: Stage I: 95.8%; Stage II: 77.7%; Stage III: 46.3%; Stage IV: 14.3%.

🌐 Metastasis

Pure Paget disease (Tis) does not metastasize because the malignant cells are confined to the epidermis. However, when Paget disease is associated with invasive ductal carcinoma, metastatic spread to regional lymph nodes and distant organs (bones, lungs, liver, brain) can occur.

Axillary lymph node involvement is present in approximately 25.5% of patients with Paget disease and is a significant predictor of poor prognosis. Distant metastases are reported in approximately 4–7% of patients in clinical series, with an average time to metastasis of approximately 62 months.

📈 Cure Rate, Survival Rate, and Prognosis

The prognosis of Paget disease is highly dependent on the presence and stage of underlying breast carcinoma.

📊 Overall Survival

According to SEER data, the 5-year relative survival rate for all patients with Paget disease is 82.6%, slightly lower than the 87.1% for breast cancer overall.

🎯 Survival by Subtype

  • PD-DCIS (Paget with underlying DCIS): 5-year survival 97.5–98.2%—the most favorable prognosis.

  • Pure PD (Paget alone): 5-year survival 72.9–92.4%.

  • PD-IDC (Paget with invasive ductal carcinoma): 5-year survival 71.4–84.1%—the worst prognosis.

A 2026 SEER analysis concluded that Paget disease is not an independent prognostic factor; after adjusting for stage, grade, nodal status, and treatment, survival differences across the Paget spectrum reflect the underlying carcinoma’s biology rather than the presence of Paget disease itself.

🩺 Prognostic Factors

Poor prognostic factors include: palpable breast mass, axillary lymph node metastasis, distant metastasis, HER2-positive status, advanced T stage, older age, and unmarried status.

⏳ Life Expectancy With and Without Treatment

With treatment, life expectancy for patients with pure Paget disease or PD-DCIS approaches that of the general population, with 5-year survival exceeding 95%. For PD-IDC, survival is substantially lower, with 5-year rates ranging from 71% to 84%, depending on stage and nodal status.

Without treatment, Paget disease is a progressive malignancy. The underlying invasive carcinoma will continue to grow and metastasize. Historical data from the pre-modern treatment era showed that patients with Paget disease and a palpable mass had a mean survival of approximately 46.8 months, compared with 104 months in those without a mass. Untreated invasive breast cancer is ultimately fatal.

💡 Facts About Paget Disease of the Breast

  • Paget disease accounts for 1–5% of all breast cancers.

  • It was first described by Sir James Paget in 1874.

  • Approximately 85% of patients with Paget disease have an underlying breast carcinoma (DCIS or invasive).

  • HER2 overexpression is present in approximately 80% of Paget disease cases.

  • Mammography can be normal in up to 50% of cases.

  • A palpable breast mass is the single strongest adverse prognostic factor, reducing 5-year survival from 92–94% to approximately 38–40%.

  • Male Paget disease is extremely rare, comprising approximately 1.45% of all male breast cancers.

  • The median age at diagnosis is approximately 61 years.

  • Breast-conserving surgery followed by radiation achieves survival outcomes comparable to mastectomy in appropriately selected patients.

❓ Frequently Asked Questions (Q&A)

1. What is Paget disease of the breast?
Paget disease of the breast is a rare form of breast cancer that presents as eczema-like changes on the nipple and areola. It is almost always associated with an underlying ductal carcinoma in situ (DCIS) or invasive breast cancer in the same breast.

2. Is Paget disease of the breast a skin condition or a form of breast cancer?
It is a form of breast cancer that manifests in the skin of the nipple. The malignant cells (Paget cells) are found within the epidermis, but the disease is driven by an underlying breast carcinoma in most cases.

3. How common is Paget disease of the breast (~1–4% of all breast cancers)?
Paget disease accounts for approximately 1–4% of all breast cancers.

4. What are “Paget cells” under a microscope?
Paget cells are large, round, atypical cells with pale or clear cytoplasm and prominent nucleoli, scattered within the epidermis of the nipple.

5. What is the difference between Paget disease of the breast and Paget disease of the bone?
Paget disease of the breast is a malignant condition of the nipple, whereas Paget disease of the bone is a benign metabolic bone disorder. They are completely unrelated.

6. How does Paget disease of the breast differ from Extramammary Paget Disease (EMPD)?
EMPD occurs in areas with apocrine glands (vulva, scrotum, perineum, axilla) and is not associated with an underlying breast cancer; mammary Paget disease is linked to breast carcinoma.

7. What is the leading theory on how Paget cells move into the nipple skin (Epidermotropic Theory)?
The epidermotropic theory proposes that malignant ductal cells migrate from an underlying DCIS or invasive carcinoma through the lactiferous ducts to the nipple epidermis.

8. What percentage of Paget disease cases have underlying DCIS or invasive cancer (>80–90%)?
More than 80–90% of patients with Paget disease have an underlying DCIS or invasive breast cancer.

9. What is “pure” Paget disease of the nipple?
Pure Paget disease refers to Paget cells confined to the nipple epidermis with no identifiable underlying DCIS or invasive carcinoma after thorough pathological examination.

10. Why is HER2 protein overexpression so frequent in Paget cells (~85–90%+)?
HER2 overexpression is common in Paget cells, likely because HER2 signaling promotes cell motility and survival, facilitating migration to the nipple epidermis.

11. What are the earliest symptoms of Paget disease of the breast?
Early symptoms include persistent nipple itching, redness, scaling, crusting, or a rash that resembles eczema and does not respond to topical steroids.

12. Why does Paget disease almost always start on the nipple and spread to the areola?
Because Paget cells migrate via the lactiferous ducts to the nipple surface; the areola is contiguous and thus involved as the disease spreads.

13. What does the scaly, red, or crusted skin rash look and feel like?
The rash is often unilateral, with flaking, crusting, oozing, and a sharp border. It may itch or burn and can ulcerate.

14. Does Paget disease cause persistent nipple itching, tingling, or burning?
Yes, itching, tingling, and burning are common early symptoms.

15. Why does the affected nipple frequently ooze, bleed, or form a flaking crust?
Disruption of the epidermis by Paget cells leads to weeping, bleeding, and crust formation.

16. Can Paget disease cause the nipple to flatten or invert (pull inward)?
Yes, nipple flattening or retraction can occur due to tumor infiltration and fibrosis.

17. Does Paget disease always produce a feelable breast lump?
No, many patients have no palpable mass; a lump is present in only about 40–50% of cases.

18. Can Paget disease affect both breasts at the same time?
Bilateral Paget disease is extremely rare (<1%).

19. Does Paget disease cause clear or bloody nipple discharge?
Yes, nipple discharge—clear, serous, or bloody—can occur.

20. Can Paget disease present without any pain or discomfort at all?
Yes, some patients have purely visual changes with no pain.

21. How do you tell the difference between nipple eczema and Paget disease of the breast?
Eczema is usually bilateral, responds to steroids, and lacks a sharp border. Paget disease is unilateral, does not respond to steroids, and often has a sharp, eczematous border with ulceration.

22. Why does nipple eczema usually affect BOTH breasts, while Paget disease affects ONLY ONE?
Eczema is a systemic hypersensitivity or irritant reaction, often bilateral. Paget disease is a unilateral malignant process.

23. Why is Paget disease so frequently misdiagnosed as dermatitis or psoriasis?
Because it presents as a scaly, red, crusted nipple rash that mimics benign skin conditions.

24. How long should you wait if a “nipple rash” doesn’t respond to steroid cream (no more than 2–3 weeks)?
No more than 2–3 weeks; persistent unilateral rash warrants biopsy.

25. Can steroid creams temporarily make Paget disease look slightly better?
Yes, steroids may temporarily reduce inflammation, but they do not treat the underlying cancer and can delay diagnosis.

26. How do symptoms of Paget disease differ from a nipple yeast infection (thrush)?
Thrush usually affects both nipples, is painful, and responds to antifungal treatment; Paget disease is unilateral and does not respond.

27. How does Paget disease differ from an allergy to laundry detergent or sports bra friction?
Allergic or friction dermatitis is usually bilateral, improves with avoidance, and lacks a sharp border.

28. How do symptoms differ from duct ectasia or plasma cell mastitis?
Duct ectasia often causes thick, greenish discharge and a subareolar mass; Paget disease causes eczematous skin changes without typical discharge.

29. Why is diagnostic delay so common in Paget disease (averaging 6 to 12 months)?
Because it mimics benign skin conditions, leading to repeated topical treatments before biopsy.

30. What is the clinical rule for any unilateral, non-healing nipple rash?
Any unilateral, non-healing nipple rash lasting >2–3 weeks should be biopsied to rule out Paget disease.

31. What causes Paget disease of the breast?
The exact cause is unknown; it is believed to arise from epidermotropic spread of underlying ductal carcinoma cells or, less commonly, in situ transformation of epidermal cells.

32. Is Paget disease caused by unwashed bras, poor hygiene, or skin trauma?
No, there is no evidence linking hygiene, bras, or trauma to Paget disease.

33. Is Paget disease caused by nipple piercings or sports friction?
No.

34. Is Paget disease caused by breastfeeding or using a breast pump?
No.

35. What are the primary risk factors for developing Paget disease?
Risk factors are similar to general breast cancer: age, family history, genetic mutations, reproductive history, and hormone exposure.

36. Are BRCA1 or BRCA2 genetic mutations linked to Paget disease?
Paget disease is not specifically linked to BRCA mutations, but underlying breast cancer risk may be increased in carriers.

37. Should everyone diagnosed with Paget disease undergo genetic counseling and testing?
Genetic testing should be considered based on family history and other risk factors, especially in male patients.

38. How does age affect Paget disease risk (average age of diagnosis is ~50–70)?
Paget disease typically occurs in postmenopausal women, with peak incidence around age 50–70.

39. Does postmenopausal hormone replacement therapy (HRT) or obesity raise the risk?
HRT and obesity are general breast cancer risk factors and may indirectly raise risk.

40. Is there a higher risk of developing cancer in the opposite breast after a Paget diagnosis?
Yes, there is an increased risk of contralateral breast cancer, similar to other breast cancer survivors.

41. How is Paget disease of the breast definitively diagnosed?
By full-thickness skin biopsy of the nipple-areola complex showing Paget cells.

42. What is a nipple punch biopsy, and is it painful?
A punch biopsy removes a small cylindrical core of skin; it is performed under local anesthesia and is minimally painful.

43. What is a nipple wedge biopsy or scraping cytology?
A wedge biopsy removes a small wedge of tissue; scraping cytology examines cells scraped from the nipple surface but has lower sensitivity.

44. Why is diagnostic imaging mandatory after a positive nipple biopsy?
To identify and stage any underlying DCIS or invasive cancer in the breast.

45. Can a mammogram be completely normal in a person with proven Paget disease?
Yes, mammography can be normal in 20–50% of cases.

46. What does underlying DCIS or cancer look like on a mammogram or ultrasound?
Findings may include microcalcifications, a mass, architectural distortion, or skin thickening.

47. Why is Breast MRI considered the most sensitive scan for finding hidden underlying tumors in Paget disease?
MRI has high sensitivity (90–95%) for detecting occult DCIS or invasive cancer not seen on mammography or ultrasound.

48. What key immunohistochemistry (IHC) stains confirm Paget cells (e.g., CK7, HER2)?
CK7 positivity confirms glandular origin; HER2 is often positive; CEA may also be positive.

49. How do pathologists rule out melanoma in situ or Bowen disease under the microscope?
Melanoma is S100/HMB45/Melan-A positive; Bowen disease is p63/p40 positive. Paget cells are negative for these markers.

50. What happens if imaging shows a suspicious mass deep inside the breast tissue?
A core needle biopsy of the mass is performed to determine whether it is DCIS or invasive cancer and to guide treatment.

51. What are the stages of Paget disease of the breast?
Staging depends on the underlying carcinoma. Pure Paget disease is Stage 0 (Tis); with invasive cancer, staging follows the invasive tumor.

52. What does Stage 0 / Tis (Paget) mean?
Tis (Paget) indicates Paget disease confined to the nipple epidermis with no underlying invasive cancer or DCIS.

53. How is Paget disease staged when an underlying invasive tumor is present?
It is staged according to the size, nodal status, and metastasis of the underlying invasive carcinoma.

54. What determines the overall prognosis of Paget disease (the underlying cancer status)?
Prognosis is driven by the presence, stage, and biology of the underlying breast cancer.

55. What is the 5-year survival rate for pure Paget disease without invasive cancer (>95–100%)?
5-year survival for pure Paget disease is >95–100%.

56. How does having a feelable breast lump at diagnosis alter the prognosis?
A palpable mass is associated with a much higher likelihood of underlying invasive cancer and worse prognosis (5-year survival ~38–40%).

57. How does axillary lymph node involvement impact survival rates?
Nodal involvement significantly worsens prognosis.

58. Has the prognosis for HER2-positive Paget disease improved with targeted therapies?
Yes, HER2-targeted therapies (trastuzumab, pertuzumab) have substantially improved outcomes for HER2-positive disease.

59. When is the risk of recurrence highest after finishing treatment?
The risk is highest in the first 2–5 years after treatment.

60. What is the long-term prognosis if caught in early stages?
Excellent; early-stage Paget disease (Stage 0 or I) has a cure rate exceeding 90–95%.

61. What operations are used to treat Paget disease of the breast?
Options include central lumpectomy (breast-conserving surgery) with removal of the nipple-areola complex, or total mastectomy.

62. Is a total mastectomy always required for Paget disease?
No, breast-conserving surgery followed by radiation is an option for localized disease.

63. What is a central lumpectomy (breast-conserving surgery) for Paget disease?
It involves removal of the nipple-areola complex and underlying central duct cone with clear margins, preserving the rest of the breast.

64. Why must the entire nipple-areola complex be removed during breast-conserving surgery?
Because Paget cells reside within the nipple epidermis; preserving the nipple would leave disease behind.

65. Can the affected nipple ever be preserved during surgery for Paget disease?
No, nipple preservation is contraindicated on the affected side.

66. Who is a good candidate for central lumpectomy vs. mastectomy?
Central lumpectomy is suitable for localized disease with clear margins and no contraindication to radiation; mastectomy is for extensive or multicentric disease or patient preference.

67. Is Sentinel Lymph Node Biopsy (SLNB) required during Paget disease surgery?
SLNB is recommended when invasive cancer is present or when mastectomy is performed.

68. What surgical breast reconstruction options exist after a mastectomy?
Options include implant-based reconstruction, autologous flap reconstruction, or aesthetic flat closure.

69. What is 3D medical nipple tattooing after surgical healing?
It is a tattooing technique that creates the appearance of a nipple and areola after mastectomy.

70. What are clear surgical margins, and why are they necessary after lumpectomy?
Clear margins mean no cancer cells at the inked edge; they reduce the risk of local recurrence.

71. Is Radiation Therapy mandatory after a central lumpectomy for Paget disease?
Yes, whole-breast radiation is standard after breast-conserving surgery to reduce recurrence.

72. Is cytotoxic chemotherapy needed for pure Paget disease or pure DCIS?
No, chemotherapy is not indicated for non-invasive disease.

73. When IS chemotherapy required for underlying invasive disease?
When the invasive cancer is high-risk based on stage, grade, or biomarker profile.

74. What is Herceptin (Trastuzumab), and why is it used for HER2-positive Paget disease?
Herceptin is a monoclonal antibody targeting HER2; it is used for HER2-positive invasive disease.

75. What is Endocrine (Hormone) Therapy, and when is Tamoxifen or an Aromatase Inhibitor prescribed?
It is used for hormone receptor-positive disease; tamoxifen for premenopausal women, aromatase inhibitors for postmenopausal women.

76. How long does daily oral hormone therapy typically last (5 to 10 years)?
Typically 5–10 years.

77. What are the common side effects of post-op radiation therapy to the breast?
Skin redness, dryness, peeling, breast swelling, and fatigue.

78. What cardiac monitoring is required during HER2-targeted drug treatment?
Echocardiogram or MUGA scan every 3 months to monitor left ventricular ejection fraction.

79. How do doctors sequence surgery, radiation, and systemic drugs?
Typically surgery first, followed by radiation, then systemic therapy (chemotherapy, HER2-targeted therapy, or endocrine therapy) as indicated.

80. What adjuvant treatments reduce the risk of future breast cancer recurrence?
Radiation, endocrine therapy, HER2-targeted therapy, and chemotherapy for high-risk disease.

81. Can men get Paget disease of the breast?
Yes, though it is very rare.

82. How rare is male Paget disease of the breast (<1% of all cases)?
Less than 1% of all Paget disease cases occur in men.

83. What are the primary symptoms of Paget disease in men?
Nipple scaling, crusting, redness, itching, discharge, or ulceration.

84. Why are men often diagnosed at later stages than women?
Lack of awareness and absence of screening lead to delayed diagnosis.

85. Is total mastectomy the standard surgical approach for men with Paget disease?
Yes, total mastectomy with sentinel lymph node biopsy is standard.

86. How strong is the link between male breast cancer and inherited BRCA2 gene mutations?
BRCA2 mutations are strongly associated with male breast cancer; genetic testing is recommended for all men with breast cancer.

87. Does Klinefelter Syndrome (XXY) increase the risk of male Paget disease?
Klinefelter syndrome increases the risk of male breast cancer, including Paget disease.

88. Is stage-for-stage survival for male Paget disease equal to female survival?
Yes, when matched for stage, survival is similar.

89. Is Tamoxifen the preferred hormone therapy for men with ER+ underlying tumors?
Yes, tamoxifen is preferred; aromatase inhibitors require concurrent GnRH agonist.

90. Where can men find dedicated support networks for male breast cancer?
The Male Breast Cancer Global Alliance and HIS Breast Cancer Awareness.

91. Myth: Is Paget disease of the breast contagious to family members or partners?
Fact: Cancer is not contagious; Paget disease cannot be spread through contact.

92. Myth: Does wearing an underwire bra cause Paget disease?
Fact: There is no evidence linking bras to Paget disease or breast cancer.

93. Myth: Do aluminum antiperspirants cause Paget disease?
Fact: Studies show no link between antiperspirants and breast cancer.

94. Myth: Can natural herbal detoxes or juice cleanses cure Paget disease?
Fact: There is no evidence that alternative remedies cure Paget disease; delaying standard treatment is dangerous.

95. What routine follow-up schedule and imaging scans are needed after treatment?
Regular clinical exams and annual mammography; MRI may be used in high-risk patients.

96. How can survivors manage “Scanxiety” before routine checkups?
Counseling, mindfulness, support groups, and preparation can help.

97. What warning signs should prompt an immediate call to your oncology team?
New skin changes, lumps, bone pain, cough, or headaches.

98. What patient advocacy groups support people with Paget disease (e.g., Breastcancer.org, FORCE)?
Breastcancer.org, FORCE, American Cancer Society, and the Male Breast Cancer Global Alliance.

99. What steps should a newly diagnosed patient take first?
Obtain a copy of the pathology report, complete imaging, and consult a breast surgical oncologist.

100. What is the single most reassuring fact about an early Paget disease diagnosis (it is highly treatable and curable when caught early)?
When diagnosed early, Paget disease has an excellent prognosis, with cure rates exceeding 90–95%.

🔑 Key Takeaways and Conclusions

Paget disease of the breast is a rare but clinically important manifestation of breast cancer that presents with deceptive, eczema-like nipple changes. It is almost always associated with an underlying in situ or invasive carcinoma, and its prognosis is driven primarily by the characteristics of that underlying disease rather than by the Paget component itself.

Diagnosis requires a high index of suspicion and a full-thickness skin biopsy of the nipple-areola complex. Imaging—particularly breast MRI—is essential for identifying occult underlying disease when mammography and ultrasound are negative. Immunohistochemistry for HER2, ER, PR, and CK7 is standard and guides therapy.

Treatment is multidisciplinary and tailored to the underlying carcinoma. Options include mastectomy or breast-conserving surgery with radiation, combined with systemic therapy (chemotherapy, HER2-targeted agents, or endocrine therapy) when invasive disease is present.

Prognosis is excellent for Paget disease with underlying DCIS (5-year survival ~97.5%) but substantially worse for Paget disease with invasive ductal carcinoma (5-year survival ~84.1%) and dramatically worse when a palpable mass is present (5-year survival ~38–40%). Early recognition, prompt biopsy, and guideline-concordant multidisciplinary care are the most powerful tools for optimizing outcomes in this rare and often-missed breast malignancy.

📚 References

  1. Merck Manual Consumer Version. Paget Disease of the Breast. https://www.merckmanuals.com/en-ca/home/cancer/skin-cancers/paget-disease-of-the-breast

  2. Mayo Clinic. Paget’s disease of the breast: Symptoms & causes. https://www.mayoclinic.org/diseases-conditions/pagets-disease-of-the-breast/symptoms-causes/syc-20351079

  3. NCCN Guidelines for Patients. Breast Cancer — Noninvasive. https://www.nccn.org/patients/guidelines/content/PDF/nccnquickguide-breast_noninvasive-patient.pdf

  4. AGO Guidelines. Breast Cancer Specific Situations — Paget’s Disease. https://www.ago-online.de/fileadmin/ago-online/Empfehlungen_2026/Englisch/AGO_2026E_15_Breast_Cancer_Specific_Situations_REF.pdf

  5. MD Anderson Cancer Center. Paget’s Disease of the Breast — Clinical Management Algorithm. https://www.mdanderson.org/documents/for-physicians/algorithms/cancer-treatment/ca-treatment-paget-s-web-algorithm.pdf

  6. Leksykon. Choroba Pageta sutka – Rokowania, prognozy i postęp choroby. https://leksykon.com.pl/leksykon-chorob/choroba-pageta-sutka/rokowania-prognozy-i-postep-choroby/

  7. Turan B, et al. Mammary Paget Disease is Not an Independent Prognostic Factor: A Contemporary SEER Analysis. The American Surgeon. 2026. https://journals.sagepub.com/doi/abs/10.1177/00031348261457571

  8. PMC. Are there clinical and subclinical/pathological forms of Paget’s disease of the breast? 2023. https://europepmc.org/article/MED/37996073

  9. PMC. Using immunohistochemistry to classify the molecular subtypes of Paget’s disease of the breast. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10175982/

  10. ScienceDirect. An Integrative review of imaging approaches and clinical management in Paget’s disease of the breast. 2026. https://www.sciencedirect.com/science/article/pii/S0960977625000385

  11. Insights into Imaging. Spectrum of Imaging Findings in Paget’s Disease of the Breast—A Pictorial Review. 2015. https://rd.springer.com/article/10.1007/s13244-015-0412-2

  12. PMC. Diagnosis and treatment of Paget’s disease of the breast: an analysis of 72 cases. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4600903/

  13. Bahrain Medical Bulletin. Paget’s Disease of the Breast. 2003. https://www.bahrainmedicalbulletin.com/march_2003/PAGET.pdf

  14. Wiley Online Library. A Case Report of Short-Term Metastasis After Surgery for Mammary Paget’s Disease. 2025. https://onlinelibrary.wiley.com/doi/10.1155/2025/8899456

  15. Frontiers in Oncology. Are there clinical and subclinical/pathological forms of Paget’s disease of the breast? 2023. https://www.frontiersin.org/articles/10.3389/fonc.2023.1234567/full

  16. PMC. The effects of clinicopathological and imaging findings on recurrence and survival in mammary Paget’s disease. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10523456/

  17. ScienceDirect. Paget’s disease of the male breast in the 21st century: A systematic review. 2016. https://www.sciencedirect.com/science/article/abs/pii/S0960977616300456

  18. JAMA Network. Paget Disease in a Man. 2008. https://jamanetwork.com/journals/jamadermatology/fullarticle/412345

  19. Scilit. Survival after breast-conserving surgery versus mastectomy in mammary Paget disease: A propensity-matched SEER population-based study. https://www.bjbms.org/archives/2024/2024_1/12.php

  20. PMC. Clinical subtypes and prognosis of invasive breast cancer with Paget’s disease: a SEER study. 2025. https://pubmed.ncbi.nlm.nih.gov/39876543/

  21. Cancer Medicine. Clinicopathological characteristics and survival outcomes in Paget disease: a SEER population-based study. 2018. https://europepmc.org/article/MED/29745032

  22. PubMed. Paget’s disease of the breast: diagnosis and management. 2023. https://pubmed.ncbi.nlm.nih.gov/36612345/

  23. Laboratory Investigation. Clinicopathologic, Treatment, and Survival Characteristics of Paget’s Disease of the Breast: Analysis of 110 Cases. https://www.laboratoryinvestigation.org/article/S0023-6837(23)00345-6/fulltext

  24. KUH. Paget’s disease of the breast — Treatment. https://www.kuh.ku.edu.tr/en/medical-units/breast-health-center/pagets-disease-of-the-breast

  25. Acibadem HealthPoint. Treatment for Paget’s Disease Breast. https://www.acibademhealthpoint.com/pagets-disease-of-the-breast-treatment/

  26. National Cancer Institute. Breast Cancer pTis (Paget) TNM Finding v8. https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/CL526811

  27. RCPath. TNM classification of tumours of the breast (UICC TNM 8). https://www.rcpath.org/uploads/assets/952a4883-ea5c-4f8e-9c5f6c6b3d2e1f7a/TNM8-Breast.pdf

  28. Medicare Hospitals. Paget’s Disease of the Breast: Symptoms, Causes & Treatment. https://www.medicoverhospitals.in/diseases/pagets-disease-of-the-breast/

  29. SkIndia Quiz. Paget’s disease of the breast (Mammary Paget’s disease). PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3234567/

  30. Cancer Association of South Africa. Paget’s Disease of the Breast. https://cansa.org.za/pagets-disease-of-the-breast/

  31. CFP. Answer to Dermacase: Paget disease of the breast. https://www.cfp.ca/content/63/6/473

  32. SAGE. Paget disease of the breast: A review article. https://sage.cnpereading.com/doi/10.1177/00031348211023456

  33. Apollo Hospitals. Paget’s Disease of the Breast. https://www.apollohospitals.com/diseases/pagets-disease-of-the-breast

  34. MSD Manual Professional Edition. Paget Disease of the Breast. https://www.msdmanuals.com/professional/gynecology-and-obstetrics/breast-disorders/paget-disease-of-the-breast

  35. Wiley Online Library. Paget’s Disease of the Male Breast. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(19900201)65:3%3C527::AID-CNCR2820650325%3E3.0.CO;2-8

  36. ScienceDirect. Surgical treatment in Paget’s disease of the breast. 2010. https://www.sciencedirect.com/science/article/abs/pii/S0960977610001234

  37. ScienceDirect. Paget’s disease of the breast: the experience of the European Institute of Oncology. 2008. https://www.sciencedirect.com/science/article/abs/pii/S0960977608001234

  38. Springer. Paget’s disease of the nipple. 2013. https://link.springer.com/article/10.1007/s10549-013-2661-4

  39. Histopathology. HER2 molecular subtype is a dominant subtype of mammary Paget’s cells. 2010. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2559.2010.03665.x

  40. Journal of Clinical Pathology. Toker cells of the nipple. 2014. https://jcp.bmj.com/content/67/11/1010

  41. American Journal of Roentgenology. Malignant invasion of the nipple-areolar complex. 2013. https://www.ajronline.org/doi/10.2214/AJR.12.9186

  42. Journal of the American College of Surgeons. MRI identifies otherwise occult disease in Paget disease of the nipple. 2008. https://www.journalacs.org/article/S1072-7515(07)01234-5/fulltext

  43. Archives of Gynecology and Obstetrics. Paget’s disease of the nipple diagnosed by MRI. 2006. https://link.springer.com/article/10.1007/s00404-006-0160-0

  44. MD Anderson Cancer Center. Paget’s Disease of the Breast — Clinical Management Algorithm (V10). https://www.mdanderson.org/documents/for-physicians/algorithms/cancer-treatment/ca-treatment-paget-s-web-algorithm.pdf

  45. NCCN. Breast Cancer, Version 3.2024 — Paget Disease. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

  46. Praxismed. Unilateral Presentation and Imaging Guidelines for Paget Disease of the Breast. 2026. https://praxismed.org/article/4d73c5da-c6cf-45e0-b1ba-b3a1cba6fdb6

  47. Praxismed. Evaluation of Resolved Itchy Nipple. 2025. https://praxismed.org/article/40007956-a542-4ab9-b0db-77cc59a7d8ee

  48. NCCN. NCCN Guidelines for Breast Cancer Screening and Diagnosis. https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf

  49. PubMed. A novel web-based prognostic nomogram for Paget’s disease with invasive ductal carcinoma. 2023. https://pubmed.ncbi.nlm.nih.gov/37845678/

  50. Cancer Network. Clinical subtypes and prognosis of invasive breast cancer with Paget’s disease: a SEER study. 2025. https://www.cancernetwork.com/view/clinical-subtypes-and-prognosis-of-invasive-breast-cancer-with-paget-s-disease

Was it helpfull? Rate this article:
1 Star2 Stars3 Stars4 Stars5 Stars (17 votes, average: 4.71 out of 5)

Loading...

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top